Lysogene:上半场2020年,商业更新

Lysogene:上半场2020年,商业更新150150Lysogene
  • 现金及现金等价物2380万€1在2020年6月30日
  • 在LYS-SAF302 FDA收到一封信按计划2020年7月2日,与没有变化预期调控时间表

法国巴黎 - 2020年7月24日在上午08:00 CEST- Lysogene(FR0013233475 - LYS)中,第3阶段的基因治疗平亚搏全站app下载台公司靶向中枢神经系统(CNS)疾病,提供H1 2020商业更新。

在2020年6月30日,现金和现金等价物总额为€2380万1(相比于2020年3月€2990万为31)。这一数额包括从2020年三月成功增资由沃脉德资本和Lysogene股东和合作伙伴Sarepta带领€7.7米所得款项总额。Lysogene认为这种现金状况为公司提供足够的财政跑道,直到Q4 2021。

与Sarepta治疗的许可和合作协议,公司还在2020年收入910万€上半年产生1在标准IFRS百分比完工项下的方法,并承认收入15“从与客户合同的收入”的应用。

此外,如预期,2020年07月02日美国FDA确认函招聘和治疗的新患者在临床试验AAVance(NCT03612869),LYS-SAF302为全球2/3期临床试验的临床持有接到公司治疗MPS IIIA的。从需求的临床保持结果的更多信息,以评估MRI表现,并特别,他们没有与临床相关的伤害。该公司将收集所需信息,以尽快解决这些问题。到目前为止,19名患者出20计划已被处理,所有患者保留在研究中,并正在遵循每个研究方案。初级和次级试验终点基于这些19例患者的分析已经登记并且对目前的开发进度没有预期的影响。

  1. 未经审计。欧元/美元汇率1.1198。的0.9124欧元/英镑汇率

1

关于Lysogene

Lysogene是基因治疗公亚搏全站app下载司集中于中枢神经系统(CNS)的罕见疾病的治疗。公司已经建立了一个独特的功能,实现安全和有效地提供基因治疗的CNS治疗溶酶体疾病和中枢神经系统的其他遗传性疾病。A相2/3临床试验在MPS IIIA与Sarepta治疗合伙公司正在进行并且在GM1神经节苷脂的相位1/3临床试验是在制备。亚博登录首页按照Lysogene和Sarepta Therapeutics公司,Sarepta治疗之间签订的协议,公司将持有的美国和欧洲以外市场的独家商业权利LYS-SAF302;和Lysogene将保持在欧洲LYS-SAF302的商业排他性。Lysogene还与对脆性X综合征,遗传性疾病与治疗孤独症的基因治疗方法的学术合作伙伴合作。亚搏全站app下载www.astridbowlby.com。

前瞻性声明

本新闻稿可能包含某些前瞻性声明,预测和估计相对于Lysogene的临床试验,临床试验数据公布,临床开发计划,预期未来的活动和Lysogene现金跑道。Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “objective”, “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

本新闻稿中的法语和英语编写的。在两个文本之间的差异的情况下,法语版将取代。

往来

斯特凡杜兰特DES奥尔努瓦

首席财务官

stephane.durant-des-aulnois@lysogene.com

33141430399

Lysogene COVID-19更新

保持联系

不要犹豫,如果你需要更多的帮助与我们联系。